Pinned Tweet
Scorpion Capital just dropped a 297-page short report on $ABVX, comparing obefazimod to DDT, dioxins, and livestock dewormer.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
Scorpion's weak $ABVX bear thesis is now pivoting to "But the North American enrollment rates were low so the data must be fake!!!"
Legitimately, 5 minutes of very simple diligence derails his point entirely, showing proof of concept to even LOWER North American enrollment rates leading to approval.
I am very serious in asking this question...Did they even look into this enrollment data *at all* before making it a key point of their bear thesis?
Replying to @ScorpionFund
Also, legitimately WTF are you talking about with this "ex-North America" enrollment bear thesis for $ABVX? Did you even try a 30 second prompt in an LLM during your supposed 11 months of "research" here?
This point doesn't even stand to very basic scrutiny. your bear point is that "only" ~10% of $ABVX patients were enrolled in North America...So? Seriously about 2 minutes with an LLM could tell you this is NOT an outlier at all.
1⃣LUCENT-1 P3 study of mirikizumab in UC ➡️ ~13% North American enrollment
2⃣LUCENT-2 P3 study of mirikizumab in UC ➡️~13% North American Enrollment
3⃣ELEVATE-UC P3 study of etrasimod in UC ➡️~9% North American Enrollment
4⃣QUASAR IS-2 P3 study of guselkumab in UC ➡️5% North American Enrollment (after the P2b study IS-1 ALSO had 5% North American patient enrollment.
All of these are **FDA approved** therapies for UC today...This COMPLETELY debunks a hinge point of your entire bear case about there being something odd about $ABVX having 10% of patients enrolled from North America.
I am being completely serious here and I want your response. DID YOU EVEN CHECK WHAT THE "NORMAL" RATES OF NORTH AMERICAN TRIAL SITE ENROLLMENT WERE IN ULCERATIVE COLITIS BEFORE YOU MADE THIS A LITERAL HINGE POINT OF YOUR BEAR THESIS FOR $ABVX?
This is truly *laughably* poor work. Readily available PoC shows FDA approval in UC on datasets not only with NA enrollment rates ~around $ABVX's, but with even *lower* rates than $ABVX has! The Guselkumab (FDA approved as Tremfya) trial had literally HALF the percentage of North American patient enrollment has $ABVX! HALF!!!
So again, I ask you...did you even bother to check into this before basing a huge chunk of your thesis on this point? Because it doesn't stand up to 30 *seconds* of midwit LLM diligence.
Here's a source for you too so that you can do the numbers yourself if you want. clinicaltrials.gov/study/NCT…
This Tremfya P3 (IS-2) had 17 patients on drug from US, and 5 from Canada. 11 patients on placebo from US and 2 from Canada. 17+5+11+2 = 35. 35/701 total patients = 4.99%. HALF the percentage of NA patient enrollment from this P3 study (that led to an FDA approved drug) as $ABVX's ~10% rate. Run the numbers on the P2b from IS1 in the same link - it's *also* 5% NA enrollment...Hello???
You're claiming that $ABVX is in trouble because of supposedly "low" NA enrollment rates...while the readily available proof of concept shows the rate can be HALF of what $ABVX has and *still* lead to approval. And this is supposedly one of your key findings you spent 11 months on? Debunking this didn't take me 11 minutes.
Awful dude - absolutely piss poor.
$ABVX I encourage all the idiot shorts who believe @ScorpionFund BULLSHIT “report” to read this thread. They blatantly lie about the data
Scorpion Capital just dropped a 297-page short report on $ABVX, comparing obefazimod to DDT, dioxins, and livestock dewormer.
12
574
Replying to @ScorpionFund
$ABVX
Oh now this is utter bullshit. You're not even telling the truth about what your own thesis was on $SLNO! you $SLNO safety problem thesis was largely based on REAL WORLD HUMAN data for that drug that had already existed for DECADES. That drug (diazoxide) had been used in other settings outside of where $SLNO was studying it for a long, long, time and there was already real world evidence of the exact side effects that you were highlighting. That had nothing to do with any preclinical work you did on the drug!
The side effects of diazoxide were literally already known for decades. It was first approved in 1973!!! your thesis there had summarily ZERO to do with whatever preclinical work you did, and the real world safety data showing an existing safety issue were already freely available in a wealth of medical literature.
This is literally the exact OPPOSITE of what you're proposing with $ABVX where the preclinical work is your entire claim and the REAL WORLD DATA DISPROVE IT. Literally the EXACT opposite of the $SLNO/diazoxide case.
Your arguments here are so poor that it is truly bizarre to see you descending to this level.
Replying to @ScorpionFund
At least your $SLNO report was based on actual in-human data.
What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show!
BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor.
I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites.
You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out.
Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"...
BTW, your own malignancy event table shows a malignancy rate BELOW background rates....???
You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you?
So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!"
BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk...
You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity...
Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
$ABVX
1) This (see screenshot), and
2) Now we now why the stock had gotten so weak in the $80s. I'm actually relieved that I now have an explanation for that.
It's legitimately a relief to find out that the seemingly inexplicable weakness in $ABVX was due to a short report that truly lacks *any* semblance of substance, or frankly even basic coherence (what even is the final claim/proposition???).
Scorpion will make some money covering on the dip that they created (like they literally admit that they are doing within the short report itself).
I suspect that the amount of money that biotech specialist funds will make buying off of this absurdity will completely dwarf whatever scraps Scorpion is taking off the table here.
I'd tell you that "I look forward to looking back at this and laughing about it someday", but the problem is...I literally already am today!
$abvx Abivax reportedly turned down a $17 billion buyout offer and went on to assemble a dream team of ulcerative colitis experts. It’s hard to believe a company would make moves of that magnitude if management knew it was sitting on a mountain of fraudulent data. The actions simply don’t align with that narrative
$ABVX Scorpion report is just silly. The entire argument is based on preclinical wet lab "research". The report makes all these outlandish claims about what the drug "might" do based on their lab work, then ignores that all of those potential "problems" have been completely debunked by ACTUAL REAL WORLD DATA.
The drug is post phase 3 already people. We already know the safety profile. The theories they published in this "short report" are *literally* the exact bear theses people were talking about 6 years ago for $ABVX. Wet lab based *theories* about the molecule itself. The difference today is that.....we literally have all the real world in human data now, AND NONE OF THOSE SCARY THEORIES TURNED OUT TO BE TRUE.
I'm with @Biohazard3737 - I increased by exposure to $ABVX this morning.
I suspect that this report coming out also explains the recent weakness in the stock. Scorpion has supposedly been working on this for 11 months. Word going around about this report is probably what caused that short report rumor and flash crash back in June too. And since then, we got EVEN MORE data proving the safety concerns are debunked. I have been baffled by even seeing the stock languishing in the $80s recently. Now I understand why that's been the case.
I've already talked to a lot of smart people on this. The near universal response is laughter/mockery. This is simply not serious work.
Congrats to Scorpion though for finding a weak stock to attack and then cover your short on a Friday Opex. $ABVX will be fine.
Continued: Look at Pfizer's FDA-approved UC drug etrasimod (Velsipity), the exact comparator Scorpion invokes. In its pivotal ELEVATE UC 12 trial, 55.4% of patients came from Eastern Europe and only 8.7% came from North America. $ABVX $PFE
Replying to @LabbRadar
Biotech veterans know why. Standard ADME, mass balance, and DDI packages live inside the confidential NDA filing to the FDA, not on investor slides or PubMed. Phase 1 healthy-volunteer ADME studies run in Europe do not even require ClinicalTrials.gov entries. $ABVX
Full ICH S10 photosafety data and clear adjudication of skin events, beyond the age-confounded NMSC cases already explained in June.
&
The complete NDA clinical pharmacology package covering repeat-dose PK, DDI, and mass balance.
$ABVX
1
2
277
$ABVX bottom line: the short report is absolute NONSENSE. Strip out the DDT theatrics and 20-year-old academic gossip, and the bull case comes down to straightforward regulatory execution on strong Phase 3 data
3
253
Scorpion quietly concedes on page 3 that calling data "undisclosed" only means their search did not find it, not that it does not exist. $ABVX
1
2
348
Their attack on ABTECT's clinical geography is equally misleading. Scorpion calls ABTECT's 10% North America and 38% Eastern Europe enrollment a smoking gun proving US doctors rejected the drug. $ABVX
5
351







